Teclistamab shows promising results in heavily pretreated multiple myeloma
Sanatate
American Association for Cancer Research Jul 12 2025 Bottom line: Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and identified a novel factor independently associated with outcomes. Journal in which the study was published: Blood Cancer Discovery , a journal of the American Association for Cancer Research (AACR). Author: Beatrice M. Razzo, MD Background: Teclistamab-
astăzi